← Back to all trials
Recruiting
NCT07041606
An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation
Conditions: Endometrial Cancer
Sex: Female
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 500
Sponsor: AstraZeneca
Location: Research Site Arkhangelsk
Summary
Multicenter, observational, prospective study of molecular profiling in advanced and aggressive endometrial cancer patients and 1-st line treatment approaches in Russian Federation
Eligibility Criteria
Inclusion Criteria:
1. Female patients aged ≥ 18 years old;
2. Signed ICF, including consent for archival FFPE tumor tissue block testing;
3. Newly diagnosed, histologically confirmed, advanced (III-IV stage) EC, with the date of diagnosis of histologically confirmed disease within 4 months before inclusion;
4. Endometrioid type G3 or any non-endometrioid histological type of EC (such as serous carcinoma, clear cell carcinoma, mixed carcinoma, undifferentiated and dedifferentiated carcinoma, carcinosarcoma, others);
5. The presence of biopsy or postoperative archival FFPE tumor sample (block);
6. Availability of source medical documentation.
Exclusion Criteria:
1\. Patients participating in clinical (interventional) studies since the diagnosis of histologically confirmed, advanced EC.
Source: ClinicalTrials.gov (NCT07041606). StuddyBuddy aggregates publicly available trial information.
